Yum Brands stock has pulled back to its breakout level. If previous resistance becomes support, that’s our buy signal.
YUM Brands stock has done a retracement to previous resistance and breakout level after reporting both earnings and revenue beats on November 2, 2017.
Continue reading “YUM Brands Stock Retracement To Previous Resistance Setup”
Sarepta Therapeutics could get European marketing approval for Exondys 51 at any time which will boost sales. Meanwhile, the company has great growth and is advancing other drugs through its pipeline.
Sarepta Therapeutics stock continues in a strong uptrend on Exondys 51.
Sarepta Therapeutics reported its last quarterly earnings data on October 25, 2017. The company reported EPS of ($0.20) versus the ($0.86) estimate. Revenue also beat coming in at $45.95 million versus the $41.29 million estimate.
Continue reading “Sarepta Therapeutics In Strong Uptrend From Exondys 51”
Earnings per share and revenue are the two main catalysts that will drive a stock either higher or lower. With earnings season coming to a close, below are the top 16 companies (listed in descending order) with earnings and/or revenue beats this earnings season.
Continue reading “Top 16 Companies With Earnings and Revenue Beats”
The top news stories this weekend that could impact stocks on the GuerillaStockTrading watch list.
Continue reading “Top Weekend News Stories November 19 2017”
Applied Materials stock has been consolidating while analysts have boosted their price targets after the company reported earnings and revenue beats.
Applied Materials stock gave a pocket pivot signal and received lots of positive analyst actions on Friday, November 17, 2017, after the company reported earnings.
Continue reading “Applied Materials Stock Gives Pocket Pivot Signal After Earnings”
Adamis Pharmaceuticals is looking at various licensing partners for its FDA approved Symjepi which will compete against Mylan’s EpiPen. As soon as the company announces a licensing partner, this stock could explode over 130 percent higher.
Adamis Pharmaceuticals was given a $10 price target by analysts at B. Riley last week. B. Riley has a Buy rating on the stock. Overall, the stock has no Sell ratings and 3 Buy ratings. The average target price is $10 which represents 138% upside from the current price of $4.20.
Continue reading “Adamis Pharmaceuticals Could Explode Over 130 Percent”
The MBS portion of balance sheet normalization appears to be missing from the current balance sheet reduction numbers. Is something wicked in the economy giving the Federal Reserve pause?
The Federal Reserve said at its September 20, 2017 meeting that the QE unwind would begin on October 1, 2017. Traders have been following this story closely because many in the alternative news sphere that sell ads for things like Bitcoin, gold, and doomsday prepper products, have stated that the Federal Reserve can’t reduce its balance sheet and that reduction is just a lie.
Continue reading “How Much Has the Federal Reserve Reduced Its Balance Sheet”
A weekly Saturday night financial show that attempts to predict market direction for the week ahead by looking at a variety of technical and fundamental indicators. Included are the top performing stocks from GuerillaStockTrading that could trend higher over the coming days and weeks driven by strong catalysts or strong fundamentals.
Continue reading “Saturday Market Prediction Show For Week of November 20 2017”
The PowerShares Global Clean Energy ETF is increasingly attracting large players investments as utility companies increase their spending on renewable energy. Utilities are likely to spend tens of billions of dollars on renewable energies over the next decade.
PowerShares Global Clean Energy ETF has large players volume that is exploding higher while the stock forms a dirty Bull Flag pattern.
Continue reading “PowerShares Global Clean Energy ETF Exploding Large Players Volume”
The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories November 16 2017”